What did @trezanderson_ actually say?
The creator claims to have lost 40 pounds in "only a few months" on semaglutide without exercising or dieting, attributing the loss entirely to appetite suppression. On side effects, they reported only "mild constipation" lasting two to three days after each dose, framing GLP-1 therapy as broadly manageable. They also promoted Mochi Health as a telehealth platform that ships obesity medication without requiring insurance.
The video is clearly a paid or affiliate promotion. The creator uses urgency framing, "Summer is right around the corner," to drive sign-ups. That context matters when evaluating how honestly the side effect picture is being painted. Telling 59,000 viewers that constipation for two days is basically the whole story is a significant oversimplification, and that's being generous.
Does the science back this up?
Partly, but the side effect picture is far more complicated than this video suggests. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide producing roughly 15% body weight loss over 68 weeks in adults with obesity, so meaningful weight loss is well-documented. Appetite suppression is a real, primary mechanism.
On side effects, the clinical trial data tells a different story than "mild constipation for a few days." In STEP 1, nausea affected 44% of participants, vomiting affected 25%, and diarrhea affected 30%. Constipation was also common at around 24%. These are not rare edge cases. A 2023 analysis in JAMA (Sodhi et al., 2023) flagged elevated risks of pancreatitis, gastroparesis, and bowel obstruction in GLP-1 users compared to those on bupropion-naltrexone. The severity and duration of gastrointestinal side effects varies widely, and for some people they are severe enough to discontinue treatment.
What did they get wrong (or right)?
The creator gets credit for one thing: "everybody's body is different" is genuinely accurate, and it's one of the more honest sentences in the video. GLP-1 side effect profiles vary considerably based on dose, titration speed, individual gut sensitivity, and baseline health status. That variability is real.
What they got wrong is more significant. Presenting constipation as the primary side effect, with the implicit message that if you can "get past that" you'll be fine, is misleading. Nausea is the most commonly reported side effect in virtually every major semaglutide trial, not constipation. The creator also implies that not eating and not exercising is a reasonable or even expected approach, which conflicts with prescribing guidelines. The FDA-approved labeling for Wegovy explicitly states it should be used alongside a reduced-calorie diet and increased physical activity. Framing weight loss without any lifestyle change as normal could set viewers up for disappointment or unsafe expectations.
What should you actually know?
GLP-1 receptor agonists like semaglutide are legitimate, evidence-backed medications for obesity. The weight loss outcomes in clinical trials are real and, for many patients, meaningful. But the side effect profile in the real world is not "mild constipation for two days." Nausea, vomiting, and fatigue are common during dose escalation. Some patients discontinue because of how severe gastrointestinal symptoms become.
A few things worth knowing before starting:
- Semaglutide is typically titrated slowly over months to reduce side effect severity. Rushing escalation increases nausea risk.
- Muscle mass loss alongside fat loss is a documented concern with rapid weight reduction. Resistance exercise and adequate protein intake are not optional extras, they matter for long-term outcomes (Wilding et al., 2021, NEJM).
- Telehealth platforms like Mochi operate legally, but patients should confirm they are receiving a proper medical evaluation, not just a prescription after a brief intake form.
- Compounded semaglutide, which many telehealth platforms have historically dispensed, is not the same as FDA-approved Wegovy or Ozempic. Potency, purity, and safety are not guaranteed equivalents.
This video is promotional content. Evaluate it accordingly.